Infex Therapeutics announces positive Phase IIa results for RESP-X in non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa
Study met its primary objective demonstrating excellent safety and tolerability, of RESP-X…
A Landmark Alliance for India’s Built Environment: IIA and COA Join Forces with Municipalika, CAPEx, and PWX 2026
National architecture bodies strengthen the event's focus on design excellence, construction innovation,…
FIRST PATIENT DOSED IN CITRYLLS PHASE IIA TRIAL EVALUATING CIT-013 IN RHEUMATOID ARTHRITIS
Randomized multi-center study designed to assess the efficacy, safety, and tolerability of…
